There are two quite different things a seller can do about dose pricing. It can tell you the price changes as the dose climbs. Or it can tell you what it changes to. Only the second is something a reader can budget against, and the gap between how often each happens is the subject of this page — one of several silences counted in what sellers do not put on the page.
How many actually print the numbers
216 sellers of 580 on this roster publish three or more distinct figures on at least one line — a ladder rather than a headline with a warning attached. That is 37% of the corpus. By contrast only 44 sellers state anywhere that their price scales with the dose, and 370 say nothing either way.
The two numbers do not overlap as neatly as they should. A seller can publish a ladder without ever writing the sentence “the price rises with your dose”, and several do. The ladder is the better disclosure in that case, because it answers the question the sentence only raises. Every seller printing a ladder is listed with its own note.
Why a ladder beats a promise
A flat-rate promise is worth more than a ladder if it holds, because it removes the question entirely. But a flat rate is a claim about the future and a ladder is a published fact about the present, and the second can be checked before ordering. The disclosure scorecard marks both, and the open-questions census counts how often neither is offered.
Counts are computed from this site’s own records at build time, most recently read October 2026. Nothing is modeled or taken from a third party.
Coby Health makes this question tangible: its semaglutide page separates dose options and purchase lengths. Read the dose and supply together before comparing figures. A table describes what is offered for sale; it does not tell you which dose a clinician will prescribe.